AI filing briefs · archive
Every 8-K brief, with filters
The whole archive: 33,711 AI briefs of material SEC Form 8-K filings by 4,788 companies: 2,325 written within three weeks of the filing (filed since Oct 19, 2026) and 31,386 written later, for past filings. Pick a month, or filter by date, 8-K item, tone, impact, topic or ticker.
Briefs on record33,711every one kept
Companies4,788with at least one brief
Recent filings2,325filed since Oct 19, 2026
Past filings31,386written later, in Nov 2026
Consolidated Water reported third-quarter 2026 revenue of $30.9 million, down 11.9% from $35.1 million, with lower services and manufacturing revenue partly offset by higher retail and bulk revenue. Net income attributable to company stockholders fell to $2.3 million, or $0.14 per diluted share, from $5.5 million, or $0.34 per diluted share, a year earlier, so shareholders saw both lower sales and lower per-share profit.
- Q3 2026 revenue $30.9 million, down 11.9% from $35.1 million; services revenue fell 31.7% to $9.8 million and manufacturing revenue fell 39.7% to $2.8 million
- Q3 net income attributable to stockholders $2.3 million ($0.14 diluted EPS) vs $5.5 million ($0.34) in Q3 2025
- Nine-month revenue $93.8 million, down 8.5%; cash and cash equivalents $129.2 million as of September 30, 2026
Read the filing on SEC.gov ↗
Microvast reported third-quarter 2026 revenue of $45.8 million, down 62.8% from $123.3 million a year earlier, and a net loss of $76.8 million, including $35.7 million of non-cash impairment charges. The company said its available cash is expected to be insufficient to meet obligations over the next twelve months, and its going concern doubt has not been alleviated, so shareholders face significant uncertainty about refinancing its debt.
- Q3 2026 revenue was $45.8 million versus $123.3 million in Q3 2025; gross margin fell to 5.2% from 37.6%.
- Q3 2026 net loss was $76.8 million, compared with a net loss of $1.5 million in Q3 2025.
- Cash, cash equivalents and restricted cash were $124.4 million at September 30, 2026; $41.7 million of convertible bonds are due on or before January 31, 2027.
- Net cash used in operating activities was $65.4 million for the nine months ended September 30, 2026.
Read the filing on SEC.gov ↗
Trevi Therapeutics reported a third-quarter 2026 net loss of $21.5 million, or $0.13 per share, up from $11.8 million, or $0.08 per share, a year earlier, as research and development expenses rose to $19.1 million from $10.1 million. The company ended the quarter with $299.4 million in cash, cash equivalents and marketable securities and said this funds cash runway into 2030, which matters to shareholders because spending is rising and the filing shows no revenue line.
- Net loss of $21.5 million for the quarter ended September 30, 2026, versus $11.8 million in the same period of 2025
- Research and development expenses of $19.1 million, up from $10.1 million, driven by Phase 3 OCEAN-1 and OCEAN-2 and Phase 2b LAKE trials
- Cash, cash equivalents and marketable securities of $299.4 million at September 30, 2026; the company expects cash runway into 2030
- Positive FDA meeting in October 2026 on the non-IPF ILD program; Phase 2 dose-ranging trial expected to start in the first quarter of 2027
Read the filing on SEC.gov ↗
Surrozen reported a third-quarter 2026 net loss of $129.7 million, up from $71.6 million a year earlier, with no related-party research revenue after the TCGFB collaboration ended. Most of the loss came from non-cash fair value changes in tranche and warrant liabilities, and the company said October financings lifted pro forma cash to about $220.3 million, with runway into 2029.
- Net loss was $129.7 million for the quarter ended September 30, 2026, including a $73.9 million non-cash loss on the tranche liability.
- Research service revenue from a related party was zero, compared with $1.0 million a year earlier, after the TCGFB collaboration terminated effective November 2025.
- Cash and cash equivalents were $100.4 million at September 30, 2026; pro forma cash was about $220.3 million after October financings.
- The company plans to expand DUET Phase 2a enrollment from about 60 to 150 patients, with Phase 1b topline data expected in the second half of 2027.
Read the filing on SEC.gov ↗
Lineage reported third-quarter 2026 results with total revenue down 1.2% to $1.36 billion, a GAAP net loss of $173 million ($0.68 per diluted share, versus a $0.44 loss a year earlier), and adjusted EBITDA down 7.0% to $317 million. CEO Greg Lehmkuhl said higher oil prices, constrained trucking capacity and tariff uncertainty created headwinds later in the quarter, and the company adjusted its full-year guidance to reflect pressures it expects to continue into the fourth quarter.
- Q3 2026 AFFO fell 14.9% to $188 million, and AFFO per share fell 14.1% to $0.73.
- Full-year 2026 guidance: adjusted EBITDA of $1.25 billion to $1.27 billion and AFFO per share of $2.86 to $2.98; the filing does not show prior guidance figures.
- Quarterly dividend declared at $0.5325 per share, an annualized rate of $2.13 per share.
- Same-store occupancy grew year over year for the second consecutive quarter; the conference call is on November 10, 2026, at 8:00 a.m. Eastern Time.
Read the filing on SEC.gov ↗
FreightCar America reported third quarter 2026 revenue of $76.5 million, down from $160.5 million a year earlier, and delivered 662 railcars versus 1,304. It posted adjusted EBITDA of $0.1 million and an adjusted net loss of $9.5 million, or $(0.28) per diluted share, compared with adjusted net income of $7.8 million a year earlier. The company reaffirmed its fiscal 2026 outlook, which matters to shareholders because it signals that management still expects the full-year targets it set on October 19.
- Q3 2026 revenue was $76.5 million versus $160.5 million in Q3 2025; railcar deliveries were 662 units versus 1,304.
- Adjusted EBITDA was $0.1 million (0.2% margin) versus $15.9 million (9.9% margin) a year earlier.
- Backlog reached 2,660 units valued at $284.5 million at September 30, 2026, up 28% from $222.0 million.
- Fiscal 2026 outlook reaffirmed: 3,100 to 3,300 railcars, revenue of $370 to $410 million, and adjusted EBITDA of $15 to $19 million.
Read the filing on SEC.gov ↗
Structure Therapeutics reported a third-quarter 2026 net loss of $144.8 million, up from $65.7 million a year earlier, as research and development expenses rose to $134.6 million from $59.0 million. The company had $1.2 billion in cash, cash equivalents and short-term investments at September 30, 2026, which it says will fund projected operations and key clinical milestones through 2028.
- Q3 2026 net loss was $144.8 million, compared with $65.7 million in Q3 2025.
- R&D expenses were $134.6 million, up from $59.0 million, mainly due to clinical trial costs.
- Cash, cash equivalents and short-term investments were $1.2 billion at September 30, 2026, down from $1.3 billion at June 30, 2026.
- Topline data from the Phase 3 ACCOMPLISH program for aleniglipron are expected in the second half of 2028.
Read the filing on SEC.gov ↗
Network-1 reported no revenue for the quarter ended September 30, 2026, and a net loss of $2,333,000, or $0.10 per share, compared with a net loss of $560,000, or $0.02 per share, a year earlier. Operating expenses rose to $1,608,000 from $800,000, mainly due to higher litigation-related professional fees, and the company also recorded a $1,060,000 loss on marketable securities in the quarter. For shareholders, the loss grew while revenue stayed at zero, and cash, cash equivalents and marketable securities totaled $31,102,000 as of September 30, 2026.
- Q3 2026 revenue was zero, the same as Q3 2025; nine-month revenue fell to zero from $150,000 a year earlier.
- Q3 2026 net loss was $2,333,000 ($0.10 per share) versus $560,000 ($0.02 per share) in Q3 2025.
- Q3 2026 operating expenses were $1,608,000 versus $800,000, driven by litigation-related professional fees.
- Cash, cash equivalents and marketable securities were $31,102,000 as of September 30, 2026; the company declared a $0.05 per share dividend in the quarter.
Read the filing on SEC.gov ↗
Attovia Therapeutics reported third quarter 2026 results on November 9, 2026, with a net loss of $22.3 million, up from $13.8 million a year earlier, and no collaboration revenue compared with $0.4 million in the prior-year quarter. The company also disclosed 12-week Phase 1b data for ATTO-1310 in chronic pruritus and high-itch atopic dermatitis, and said it expects two Phase 2 trials to start in the first half of 2027. Cash, cash equivalents, and marketable securities of $395.9 million are expected to fund operations into 2030.
- Net loss was $22.3 million for Q3 2026, compared with $13.8 million for Q3 2025.
- Collaboration revenue was zero in Q3 2026, compared with $0.4 million in Q3 2025.
- Research and development expenses rose to $20.3 million from $12.3 million, driven by ATTO-1310 and preclinical programs.
- At Week 12 in chronic pruritus patients, 82% of ATTO-1310-treated patients achieved PP-NRS4 vs. 22% with placebo; Phase 2 ATTUNE trials are on track to start in the first half of 2027.
Read the filing on SEC.gov ↗
Ethan Allen reported fiscal 2027 first-quarter results for the period ended September 30, 2026, with consolidated net sales down 11.8% year over year and GAAP diluted EPS falling to $0.07 from $0.41. Adjusted diluted EPS was $0.10 versus $0.43 a year earlier, and the company cited lower sales and tariffs for the margin pressure. The filing contains no updated financial guidance.
- Consolidated net sales were $129.6 million, compared with $147.0 million in the prior year period.
- GAAP net income was $1.7 million, compared with $10.5 million; GAAP operating margin was 1.3%, compared with 6.8%.
- Cash and cash equivalents were $92.2 million at September 30, 2026, after $92.2 million in dividends paid during the quarter, with no outstanding debt.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.